transposition of the new Directive into our law, by, for example, reducing the number of Home Office inspectors or the number of inspections they carry out each year.
The concerns of Lord Wills were echoed by Lord Rosser, but it was not surprising that the comments of Lord Willis (Chair of the Association of Medical Research Charities), Professor Lord Winston (the gynaecologist and TV personality), Lord Taverne (a lawyer and former Chairman of the Research Defence Society), and Baroness Warwick (Chair of the Human Tissue Authority) emphasised the past and future importance of animal experimentation. There were no outright antivivisectionist comments -perhaps there are no antivivisectionists in the House of Lords, or, if there are, they were not present on 24 October.
Two aspects of the debate are worthy of particular attention. First, as is customary, the debate concluded with a reply by a Government Minister, who, on this occasion, was a Minister of State at the Home Office, Lord Henley. I could add, by the way, that the reply to the House of Commons debate, by the Under-Secretary of State, Lynne Featherstone, was also worth noting.
Lord Henley emphasised the need for balance between the need for research and the need for effective [animal] protection, but, somewhat worryingly, said that the new Directive would offer opportunities for reducing "unnecessary bureaucracy" and "stream lining our existing processes". However, to be fair, he also emphasised that "we will certainly not be looking to reduce our standards in any way whatever". This, he said, would be via Article 2 of the Directive, "which provides a mechanism that we can use to retain current higher UK standards" -this would include maintaining a "strong and properly resourced inspectorate".
Other important points made by Lord Henley referred to greater transparency about animal use, continuation of the ban on the use of great apes, and supporting research aimed at replacing the use of non-human primates, as well as reducing the use of laboratory animals in general, through the development of alternatives.
I am sure that I will not be alone in looking carefully to see how Lord Henley's assurances are reflected in the various announcements to be made by the Government in the first half of 2012. However, it was another part of the House of Lords debate which really intrigued me.
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Lord Winston said that "there is a case for having legislation to make it clear that a particular drug has only been possible for human consumption because of animal testing". This, he said, "could be stamped on the packet, rather like a [notice on a] cigarette packet". I wondered what this announcement would be, and whether it was a proposal that had been carefully thought through, or was merely a sound bite opportunity of the kind that celebrities like to take or create. 5 
Lord
Taverne provided an answer, when he said that "it would be beneficial if every general practice surgery displayed a notice stating, 'All the drugs used or recommended in this surgery have been tested on animals' ".
I cannot imagine that my health centre would welcome that suggestion, especially if it were a legal requirement, as it might lead to lots of questions and complaints from patients. Also, I could not see how there could be enough space on the drug packet itself. I therefore decided to look at the manufacturers' leaflets which accompany the five different drugs I take every day. I should say that there was a degree of self-sacrifice in this, since it has long been my policy never to look up my illnesses on the Internet or in Home Doctor books, and never to read the manufacturers' leaflets.
I must say that I was rather shocked, when I saw that, in addition to statements about what the drugs were for, there were long lists of reasons for not taking them, of needs for special care when doing so, of other precautions, and of problems when taking other medicines as well, with or without prescriptions. Worst of all, of course, was the list of possible side-effects, which are listed, for my five drugs, in Table 1 .
What, then, could the manufacturers say on their leaflets, bearing in mind the need for greater transparency? I have had some experience of the difficulties associated with honest labelling, as, more than 20 years ago, I was asked to produce a report for the European Commission on labelling related to the animal testing of cosmetic ingredients and products. I concluded that the use of terms such as 'cruelty-free' or 'not tested on animals' resulted in confusion engendered by their misuse, which compromised legitimate concerns for both human and animal welfare, and led to unfair trading practices, so such misleading terminology should be prohibited within the EEC. 6 It is obvious that labelling drugs in relation to animal testing would be much, much more difficult, and the rather superficial suggestions of Lord Winston and Lord Taverne just would not do. Something more like this would be needed:
"Testing on animals: Despite the fact that thousands of animals were used in the discovery and development of this product, no guarantee can be offered that it will work or be sufficiently safe in your case. This is because animals and humans are significantly different in terms of their physiology, pathology and responses to drugs, so laboratory animals can usually provide only poor models of human diseases and responses to possible therapies. In addition, the animal tests conducted took little or no account of human genetic variation, of differences in human geographical, societal, occupational or lifestyle factors, of the simultaneous incidence of other diseases, or of the concurrent use of other drugs. It is for these reasons that it must be admitted that there are insuperable uncertainties about the efficacy of the product and the risk of potentially serious side-effects of many kinds". I am sure that company and Government lawyers would have a field-day as they sought to agree on an acceptable terminology of this kind. However, I want to emphasise that I do not wish to seem to be attacking anybody. All I ask is that, faced with complex situations, we think very carefully before we speak. This should apply no less to those elevated to the House of Lords than to the rest of us.
Nor do I wish to seem to be unduly critical of the pharmaceutical industry. I think they do a marvellous job in increasing the length and quality of life, bearing in mind the highly complex situations and populations with which they are faced. Personally, I am grateful that my heart is still beating, that my blood glucose and cholesterol levels are low, that my blood doesn't clot too readily, that my blood pressure is under control and that my vital organs appear to be able to bear the strain. Not all patients are so fortunate, however.
Nevertheless, as has been pointed out in many publications, including a recent ATLA Editorial, 7 the pharmaceutical industry is in a state of crisis, partly because many drugs have had to be withdrawn late on during development, during clinical trials, and even after they have been accepted for use at the population level, sometimes because of lack of efficacy, and sometimes because of unexpected toxicity. For example, drug-induced liver injury (DILI) is one of the most common reasons for such withdrawals, since human toxicity is rarely predictable from the pharmacological actions of drugs, and that the concordance between animal toxicity is so poor that animal studies cannot contribute effectively to the decision-making process. The failure to detect DILI at a sufficiently early stage results in both a huge financial cost for the pharmaceutical industry and a real human cost for the patient -75% of the individuals who suffer idiosyncratic liver injury either die or require a transplant. The need for urgent action on DILI has been recognised by the pharmaceutical industry and by national and international government agencies, including the US Food and Drug Administration (FDA) and the European Innovative Medicines Initiative (IMI).
On 3 November, the 13th Annual FRAME As I concluded in that other Editorial, 7 "In the light of the application of the multivarious, rapidly-developing, more human-focused, new technologies, and recognition of the importance of two-way translation between the laboratory and the clinic, there is every prospect that the invention and application of medicines will be re-invigorated and that many of the problems associated with drug side-effects will be solved, with consequent benefits to the industry and, more importantly, to the patients. Make no mistake, the days of the animal-models-tell-us-all and one-drugsuits-all philosophies are over."
The day will surely come, when 'Not tested on animals' will be the expected norm on drug packages and the accompanying, now more reassuring, manufacturers' leaflets. 
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